Unknown

Dataset Information

0

Phase 1 trial, pharmacokinetics, and pharmacodynamics of dasatinib combined with crizotinib in children with recurrent or progressive high-grade and diffuse intrinsic pontine glioma.


ABSTRACT: BACKGROUND:Progressive/recurrent high-grade and diffuse intrinsic pontine gliomas (DIPGs) are fatal. Treatments targeting molecular pathways critical for these cancers are needed. METHODS:We conducted a phase 1 study (rolling-six design) to establish the safety and maximum tolerated dose (MTD) of dasatinib, an oral platelet-derived growth factor receptor A (PDGFRA) inhibitor, and crizotinib, an oral c-Met inhibitor, in such patients. Pharmacokinetics of both agents were performed. Biomarkers of cellular pathway activation in peripheral-blood mononuclear cells (PBMC) were evaluated before and after administration of dasatinib. PDGFRA and MET amplification, and PDGFRA mutations were studied in tumor samples. RESULTS:Twenty-five patients were enrolled in this study (median age: 11.9 years). Eleven patients had DIPG. Glioblastoma accounted for 40% of cases. Dasatinib at 50 mg/m2 and crizotinib at 130 mg/m2 or 100 mg/m2 were poorly tolerated when administered twice daily. Drug administration was then switched to once daily. Dasatinib administered at 50 mg/m2 and crizotinib at 215 mg/m2 once daily was the MTD. Dose-limiting toxicities consisted of diarrhea, fatigue, proteinuria, hyponatremia, rash, and grade 4 neutropenia. Only two patients received therapy for at least 6 months. No objective radiologic responses were observed. Pharmacokinetics of dasatinib and crizotinib were comparable to previous studies. A statistically significant decrease in the ratio of p-AKT/total AKT in PBMC occurred after dasatinib administration. PDGFRA and MET amplification were found in four and two cases, respectively. Only one of 10 tumors harbored a PDGFRA mutation. CONCLUSIONS:This drug combination was poorly tolerated and its activity was minimal. We do not recommend further testing of this combination in children.

SUBMITTER: Broniscer A 

PROVIDER: S-EPMC5980705 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Phase 1 trial, pharmacokinetics, and pharmacodynamics of dasatinib combined with crizotinib in children with recurrent or progressive high-grade and diffuse intrinsic pontine glioma.

Broniscer Alberto A   Jia Sujuan S   Mandrell Belinda B   Hamideh Dima D   Huang Jie J   Onar-Thomas Arzu A   Gajjar Amar A   Raimondi Susana C SC   Tatevossian Ruth G RG   Stewart Clinton F CF  

Pediatric blood & cancer 20180307 7


<h4>Background</h4>Progressive/recurrent high-grade and diffuse intrinsic pontine gliomas (DIPGs) are fatal. Treatments targeting molecular pathways critical for these cancers are needed.<h4>Methods</h4>We conducted a phase 1 study (rolling-six design) to establish the safety and maximum tolerated dose (MTD) of dasatinib, an oral platelet-derived growth factor receptor A (PDGFRA) inhibitor, and crizotinib, an oral c-Met inhibitor, in such patients. Pharmacokinetics of both agents were performed.  ...[more]

Similar Datasets

| S-EPMC3685168 | biostudies-literature
2014-03-31 | E-GEOD-50025 | biostudies-arrayexpress
2014-03-31 | GSE50025 | GEO
| S-EPMC4056452 | biostudies-literature
| S-EPMC5327462 | biostudies-literature
| S-EPMC5462626 | biostudies-literature
| S-EPMC5368268 | biostudies-literature
| S-EPMC5637314 | biostudies-literature
| S-EPMC6113938 | biostudies-other
| S-EPMC6477298 | biostudies-literature